Elicio Therapeutics (Nasdaq: ELTX) held a virtual expert meeting on November 11 to discuss clinical development of camupepimut for KRAS-mutated pancreatic ductal adenocarcinoma, including potential use in neoadjuvant and metastatic settings. The discussion offered investors an update on the company’s clinical program, but the available meeting record included no efficacy, safety or enrollment data.
Elicio’s head of research and chief medical officer, Christopher Haqq, moderated the session. The invited pancreatic cancer specialists were Kevin Soares and Eileen O’Reilly.
Phase 1 neoadjuvant study is underway
Haqq said Soares is the principal investigator of a Phase 1 neoadjuvant study incorporating camupepimut into a treatment regimen. The company recently launched the study and had received a number of questions about it, Haqq said, prompting the meeting. Soares is an assistant attending surgeon on the hepatopancreatobiliary surgery team at Memorial Sloan Kettering Cancer Center in New York.
Neoadjuvant treatment is given before surgery. The meeting record confirms that the study is in Phase 1 and has started, but provides no details on its design, enrollment, treatment regimen or expected completion date. It also reports no clinical results, so the available information does not establish how camupepimut is performing in the trial or what its safety profile may be.
Discussion also covered metastatic disease
The agenda included camupepimut’s development for metastatic pancreatic cancer. Haqq introduced both invited specialists, including O’Reilly, but the available record does not include her specific remarks or details on the design, phase or progress of any trial in metastatic disease.
At the outset, Haqq noted that the event included forward-looking statements and said the relevant disclosure was available on Elicio’s website. The record cuts off while introducing O’Reilly’s position, so it does not show the discussion’s conclusions. It also contains no new clinical data, regulatory decisions or updates to the company’s development timeline.
Quarterly results are separate from clinical progress
A quarterly earnings summary included with the meeting materials said Elicio reported a third-quarter loss of $0.30 per share on November 5, 2026, $0.13 less than expected. Revenue was $0, in line with expectations. Those financial results are separate from the clinical discussion: a smaller-than-expected loss does not indicate progress for the drug candidate, and the revenue figure provides no details about camupepimut’s development costs or funding.
The confirmed clinical update is that Elicio has started a Phase 1 neoadjuvant study for KRAS-mutated pancreatic ductal adenocarcinoma and held a discussion about potential use in both neoadjuvant and metastatic settings. The available meeting record contains no trial data or follow-up Q&A further information on the program will depend on subsequent company disclosures.